Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years

被引：113

作者：

Schwarz, Tino F. ^{[1
]}

Spaczynski, Marek ^{[2
]}

Schneider, Achim ^{[3
,4
]}

Wysocki, Jacek ^{[5
]}

Galaj, Andrzej ^{[6
]}

Perona, Pamela ^{[7
]}

Poncelet, Sylviane ^{[8
]}

Zahaf, Toufik ^{[8
]}

Hardt, Karin ^{[8
]}

Descamps, Dominique ^{[8
]}

Dubin, Gary ^{[9
]}

机构：

[1] Stiftung Juliusspital Wurzburg, D-97070 Wurzburg, Germany

[2] Katedra Ginekol Poloznictwa Klin Onkol, Poznan, Poland

[3] Charite, D-12200 Berlin, Germany

[4] Dept Gynaecol, Berlin, Germany

[5] Univ Sch Med Sci, Dept Prevent Med, Poznan, Poland

[6] Vitamed Bydgoszcz, Bydgoszcz, Poland

[7] Univ Munich, Dept Trop Med & Infect Dis, D-80802 Munich, Germany

[8] GlaxoSmithKline Biol, B-1330 Rixensart, Belgium

[9] GlaxoSmithKline Biol, King Of Prussia, PA 19406 USA

来源：

VACCINE | 2009年 / 27卷 / 04期

关键词：

AS04; Adjuvant; Cervical cancer; HPV; Immunization; HUMAN-PAPILLOMAVIRUS TYPE-16; HEPATITIS-B-VACCINE; PARTICLE VACCINE; YOUNG-WOMEN; FOLLOW-UP; EFFICACY; INFECTION; PREVALENCE; ANTIBODIES; LESIONS;

D O I：

10.1016/j.vaccine.2008.10.088

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The immunogenicity and safety of an HIIV-16/18 AS04-adjuvanted vaccine were assessed in women aged 26-55 years and compared with women aged 15-25 years in a Phase III, non-randomised, open-label, age-stratified study. Overall the vaccine was well tolerated and 100% seropositivity was achieved I month after the third dose in all age groups. There was a high correlation between HPV-16 and HPV-18 antibody levels (IgG) in cervicovaginal secretions and sera, regardless of age. The HPV-16/18 AS04-adjuvanted vaccine induces a robust and persistent immune response in women >26 years of age and generates antibodies that transudate through the cervix epithelium. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：581 / 587

页数：7

共 31 条

[1] Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine [J].

Bernstein, DI ;

Aoki, FY ;

Tyring, SK ;

Stanberry, LR ;

St Pierre, C ;

Shafran, SD ;

Leroux-Roels, G ;

Van Herck, K ;

Bollaerts, A ;

Dubin, G .

CLINICAL INFECTIOUS DISEASES, 2005, 40 (09) :1271-1281

[2] Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04 [J].

Boland, G ;

Beran, J ;

Lievens, M ;

Sasadeusz, J ;

Dentico, P ;

Nothdurft, H ;

Zuckerman, JN ;

Genton, B ;

Steffen, R ;

Loutan, L ;

Van Hattum, J ;

Stoffel, M .

VACCINE, 2004, 23 (03) :316-320

[3] The causal relation between human papillomavirus and cervical cancer [J].

Bosch, FX ;

Lorincz, A ;

Muñoz, N ;

Meijer, CJLM ;

Shah, KV .

JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (04) :244-265

[4] Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection [J].

Carter, JJ ;

Koutsky, LA ;

Hughes, JP ;

Lee, SK ;

Kuypers, J ;

Kiviat, N ;

Galloway, DA .

JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (06) :1911-1919

[5] A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica [J].

Castle, PE ;

Schiffman, M ;

Herrero, R ;

Hildesheim, A ;

Rodriguez, AC ;

Bratti, MC ;

Sherman, ME ;

Wacholder, S ;

Tarone, R ;

Burk, RD .

JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (11) :1808-1816

[6] Comparison of ophthalmic sponges for measurements of immune markers from cervical secretions [J].

Castle, PE ;

Rodriguez, AC ;

Bowman, FP ;

Herrero, R ;

Schiffman, M ;

Bratti, MC ;

Morera, LA ;

Schust, D ;

Crowley-Nowick, P ;

Hildesheim, A .

CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2004, 11 (02) :399-405

[7] Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis [J].

Clifford, GM ;

Smith, JS ;

Aguado, T ;

Franceschi, S .

BRITISH JOURNAL OF CANCER, 2003, 89 (01) :101-105

[8] Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology:: a meta-analysis [J].

de Sanjose, Silvia ;

Diaz, Mireia ;

Castellsague, Xavier ;

Clifford, Gary ;

Bruni, Laia ;

Munoz, Nubia ;

Bosch, F. Xavier .

LANCET INFECTIOUS DISEASES, 2007, 7 (07) :453-459

[9] The effect of age on immunologic response to recombinant hepatitis B vaccine: A meta-analysis [J].

Fisman, DN ;

Agrawal, D ;

Leder, K .

CLINICAL INFECTIOUS DISEASES, 2002, 35 (11) :1368-1375

[10] GlaxoSmithKline Adjuvant systems in vaccines: concepts, achievements and perspectives [J].

Garcon, Nathalie ;

Chomez, Patrick ;

Van Mechelen, Marcelle .

EXPERT REVIEW OF VACCINES, 2007, 6 (05) :723-739

← 1 2 3 4 →